It was also observed in population studies that chemotherapy significantly improved the survival rate of patients with low PYCR1 expression at the early stage of breast cancer, which confirmed that the lack of PYCR1 might enhance the chemosensitivity of doxorubicin to breast cancer (32). Here, PYCR1 is linked to breast carcinoma.